长效整合酶抑制剂拉替拉韦（raltegravir）联合优化背景治疗方案治疗经治耐药 HIV 感染患者的长期疗效和安全性：BENCHMRK 1 和 2 期临床试验的第 96 周结果。
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
机构信息
State University of New York at Stony Brook, The Rockefeller University, New York, New York, USA.
出版信息
Clin Infect Dis. 2010 Feb 15;50(4):605-12. doi: 10.1086/650002.
BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class drug-resistant human immunodeficiency virus infection. At week 96 (combined data), raltegravir (400 mg twice daily) plus optimized background therapy was generally well tolerated, with superior and durable antiretroviral and immunological efficacy, compared with optimized background therapy alone.
BENCHMRK-1 和 -2 是正在进行的、针对三重耐药人类免疫缺陷病毒感染且经抗逆转录病毒治疗失败的患者的、关于拉替拉韦的双盲 III 期研究。在第 96 周（合并数据），与优化背景治疗相比，拉替拉韦（400 mg 每日两次）联合优化背景治疗具有更好的耐受性、更持久的抗病毒和免疫疗效。
Zotero 插件